<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132957">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098278</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-2003-203</org_study_id>
    <nct_id>NCT02098278</nct_id>
  </id_info>
  <brief_title>Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia</brief_title>
  <official_title>A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with
      chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and
      chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride
      clearance.

      This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for
      12 weeks during the 13 week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change from baseline in fasting triglycerides in patients with chylomicronemia</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change from baseline on chylomicron triglyceride clearance</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change from baseline in plasma non-HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Lipoprotein Lipase Deficiency, Familial</condition>
  <condition>Hyperlipoproteinemia Type I</condition>
  <condition>Chylomicronemia, Familial</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>CAT-2003 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-2003</intervention_name>
    <arm_group_label>CAT-2003 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>CAT-2003 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Familial Chylomicronemia (Fasting triglycerides ≥ 885 mg/dL at Screening and
             documented history of plasma post-heparin LDL activity &lt; 20% of normal or genetic
             confirmation of homozygosity or compound heterozygosity for loss-of-function
             mutations in familial chylomicronemia-causing genes) OR

          -  Non-familial Chylomicronemia (Fasting triglycerides ≥ 442 mg/dL at Screening and
             documented history of fasting triglycerides ≥  885 mg/dL)

        Key Exclusion Criteria:

          -  History of any major cardiovascular event within 6 months of Screening

          -  Type I diabetes mellitus or use of insulin

          -  History of pancreatitis within 3 month of Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joanne Donovan, MD, PhD</last_name>
    <phone>(617) 349-1971</phone>
    <email>clinical@catabasis.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
